Biopsy tolerance study ends early – what we know
NCT ID NCT05022420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to understand how well patients tolerate biopsies for autoimmune diseases and whether they feel properly informed. It planned to enroll 505 people but was terminated early. The results may help improve patient experience with these common procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
505 people
The number who actually took part.
- Started
-
Aug 2021
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
all patients that underwent a biospy for his auto-immune rare disease
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * biospy required for the diagnsis or follow up aged of more than 18 non opposition form Exclusion Criteria: * unable to consent demencia unable to fill the form and questionnaire patient Under juridical protection refusing to participate
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autoimmune disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH de Quimper
Quimper, 20007, France
-
CHRU de Brest
Brest, 29609, France
-
CHU d'ANGERS
Angers, France
-
CHU de Bordeaux
Bordeaux, 33000, France
-
CHU de LILLE
Lille, 59037, France
-
CHU de Marseille
Marseille, France
-
CHU de Tours
Tours, France
-
Hôpital de la Salpétrière
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire predict who will suffer from a urinary stent?
- Could KP405 offer a new way to tackle Parkinson's?
- Could colonoscopy prep become a pill instead of a gallon of liquid?
- Genetic hunt for hidden causes of mysterious inflammatory diseases
- Could a single injection reprogram immune cells to tame lupus and scleroderma?
- Your genes, your meds: 1200-Patient study tests smarter prescribing